Advanced Hepatocellular Carcinoma
Conditions
Brief summary
This study is a clinical study to explore the efficacy and safety of BL-B01D1 monotherapy, BL-B01D1 in combination with lenvatinib, BL-B01D1 in combination with PD-1 monoclonal antibody, and BL-B01D1 in combination with PD-1 monoclonal antibody and bevacizumab in patients with advanced hepatocellular carcinoma.
Interventions
DRUGBL-B01D1
Administration by intravenous infusion for a cycle of 3 weeks.
DRUGLenvatinib
8mg (body weight \< 60kg), or 12mg (body weight ≥60kg), QD.
DRUGFinotonlimab
Administration by intravenous infusion for a cycle of 3 weeks.
DRUGBevacizumab
Administration by intravenous infusion for a cycle of 3 weeks.
Sponsors
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Sign the informed consent form voluntarily and follow the protocol requirements; 2. Gender is not limited; 3. Age ≥18 years old and ≤75 years old; 4. Expected survival time ≥3 months; 5. Patients with advanced HCC confirmed by histology or cytology; 6. Consent to provide archived tumor tissue samples or fresh tissue samples from the primary or metastatic lesions; 7. At least one measurable lesion meeting the RECIST v1.1 definition was required; 8. ECOG score was 0-1; 9. The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0; 10. No severe cardiac dysfunction, left ventricular ejection fraction ≥50%; 11. Organ function level must meet the requirements; 12. Coagulation function: international normalized ratio (INR) ≤1.5×ULN, and activated partial thromboplastin time (APTT) ≤1.5×ULN; 13. Urinary protein ≤2+ or ≤1000mg/24h; 14. No cirrhosis or only Child-Pugh A cirrhosis; 15. If hepatitis B virus infection is negative or positive, the status of HBV surface antigen (HBsAg) should be confirmed by HBV serological test; 16. For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before the start of treatment, a serum or urine pregnancy test must be negative, and the patient must not be lactating; All enrolled patients should take adequate barrier contraception during the entire treatment cycle and for 6 months after the end of treatment.
Exclusion criteria
1. Patients with active central nervous system metastases; 2. Who had participated in any other clinical trial within 4 weeks before the trial dose; 3. Received anti-tumor therapy such as chemotherapy, radiotherapy and biological therapy within 4 weeks before the first use of study drug; 4. Had undergone major surgery (investigator-defined) within 4 weeks before the first dose; 5. Systemic corticosteroids or immunosuppressive therapy is required within 2 weeks before study dosing; 6. Pulmonary disease defined as ≥ grade 3 according to NCI-CTCAE v5.0; A history of ILD/pulmonary inflammation requiring steroid treatment; 7. Serious systemic infection within 4 weeks before screening; 8. Patients at risk for active autoimmune disease or with a history of autoimmune disease; 9. Other malignant tumors within 5 years before the first treatment; 10. Human immunodeficiency virus antibody positive, active tuberculosis or hepatitis C virus infection; 11. Poorly controlled hypertension by two antihypertensive drugs with different mechanisms; 12. Diabetic patients with poor glycemic control; 13. Had a history of severe cardiovascular and cerebrovascular diseases; 14. Previous history of autologous or allogeneic stem cell, bone marrow or organ transplantation; 15. Subjects with clinically significant bleeding or significant bleeding tendency within the previous 4 weeks were screened; 16. Patients with massive or symptomatic effusions or poorly controlled effusions; 17. Imaging examination showed that the tumor had invaded or wrapped around the chest, neck, pharynx and other large arteries or invaded the pericardium and heart; 18. Unstable thrombotic events requiring therapeutic intervention within 6 months before screening; 19. Prior treatment with an ADC drug with a topoisomerase I inhibitor as a toxin; 20. Patients with a history of allergy to recombinant humanized antibodies or to any excipients of the trial drug; 21. The cumulative dose of anthracyclines \> 360 mg/m2 in previous (new) adjuvant therapy; 22. Pregnant or lactating women; 23. Who have a history of psychotropic drug abuse and cannot quit or have mental disorders; 24. Other conditions for trial participation were not considered appropriate by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) | Up to approximately 24 months | Objective response rate (ORR) is defined as the number of CR and PR in the treatment and control groups divided by the number of that group in the full analysis set (FAS). |
| Recommended Phase II Dose (RP2D) | Up to approximately 24 months | The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study of BL-B01D1. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival (PFS) | Up to approximately 24 months | Progression-free survival (PFS) as assessed by BICR is defined as the time between the date subjects are randomized and the first observation of disease progression (based on BICR's image-based assessment) or death. |
| Disease Control Rate (DCR) | Up to approximately 24 months | Disease Control Rate (DCR) : Percentage of all randomized subjects who rated the best overall response (BOR) as complete response (CR), partial response (PR), and disease stabilization (SD) according to RECIST 1.1 criteria. |
| Duration of Response (DOR) | Up to approximately 24 months | Duration of Response (DOR) is defined as the period from the date when tumor response is first recorded to the date when objective tumor progression is first recorded or the date of death. |
| Treatment Emergent Adverse Event (TEAE) | Up to approximately 24 months | TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of BL-B01D1. The type, frequency and severity of TEAE will be evaluated during the treatment of BL-B01D1. |
Countries
China
Contacts
CONTACTSa Xiao, PHD
Outcome results
None listed